title: Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
abstract: Treatment with the dipeptidyl peptidase-4 inhibitor, anagliptin, or with the α-glucosidase inhibitor, miglitol, reduced the oral sucrose load-inducible expression of interleukin (IL)-1β, IL-18, tumor necrosis factor-α, S100a8, S100a9, S100a11, IL-1R2, IL-1Rn and tumor necrosis factor receptor 2 genes in peripheral leukocytes of Otsuka Long-Evans Tokushima fatty (OLETF) rats at the stage of impaired glucose tolerance. Inhibiting postprandial hyperglycemia reduced the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
authors.affiliation: Laboratory of Nutritional Physiology, Graduate School of Nutritional and Environmental Sciences, The University of Shizuoka.
authors.forename: Chihiro
authors.initials: C
authors.lastname: Imai
authors.forename: Tomomi
authors.initials: T
authors.lastname: Harazaki
authors.forename: Seiya
authors.initials: S
authors.lastname: Inoue
authors.forename: Kazuki
authors.initials: K
authors.lastname: Mochizuki
authors.forename: Toshinao
authors.initials: T
authors.lastname: Goda
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D018819:Dipeptidyl Peptidase 4 / Q000235:genetics / Q000276:immunology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D006943:Hyperglycemia / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D007328:Insulin / Q000378:metabolism; D020382:Interleukin-18 / Q000235:genetics / Q000276:immunology; D053583:Interleukin-1beta / Q000235:genetics / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D020334:Rats, Inbred OLETF; D017472:Receptors, Interleukin-1 / Q000235:genetics / Q000276:immunology; D009418:S100 Proteins / Q000235:genetics / Q000276:immunology; D013395:Sucrose / Q000008:administration & dosage; D047992:TNF Receptor-Associated Factor 2 / Q000235:genetics / Q000276:immunology; D000520:alpha-Glucosidases / Q000235:genetics / Q000276:immunology
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D020382:Interleukin-18; D053583:Interleukin-1beta; D011743:Pyrimidines; D017472:Receptors, Interleukin-1; D009418:S100 Proteins; D047992:TNF Receptor-Associated Factor 2; C045621:miglitol; D017485:1-Deoxynojirimycin; D013395:Sucrose; D000520:alpha-Glucosidases; D018819:Dipeptidyl Peptidase 4; C583175:anagliptin